Troglitazone Inhibits Matrix Metalloproteinase-9 Expression and Invasion of Breast Cancer Cell through a Peroxisome Proliferator-Activated Receptor γ-Dependent Mechanism

Peroxisome proliferator-activated receptor γ (PPARγ) is involved in the pathology of numerous diseases including atherosclerosis, diabetes, obesity, and cancer. Matrix metalloproteinases (MMPs) play a significant role in tissue remodeling related to various processes such as morphogenesis, angiogene...

Full description

Saved in:
Bibliographic Details
Published inJournal of breast cancer Vol. 21; no. 1; pp. 28 - 36
Main Authors Hong, On-Yu, Youn, Hyun Jo, Jang, Hye-Yeon, Jung, Sung Hoo, Noh, Eun-Mi, Chae, Hee Suk, Jeong, Young-Ju, Kim, Won, Kim, Cheorl-Ho, Kim, Jong-Suk
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Breast Cancer Society 01.03.2018
한국유방암학회
Subjects
Online AccessGet full text
ISSN1738-6756
2092-9900
DOI10.4048/jbc.2018.21.1.28

Cover

Loading…
More Information
Summary:Peroxisome proliferator-activated receptor γ (PPARγ) is involved in the pathology of numerous diseases including atherosclerosis, diabetes, obesity, and cancer. Matrix metalloproteinases (MMPs) play a significant role in tissue remodeling related to various processes such as morphogenesis, angiogenesis, tissue repair, invasion, and metastasis. We investigated the effects of PPARγ on MMP expression and invasion in breast cancer cells. MCF-7 cells were cultured and then cell viability was monitored in an MTT assay. Western blotting, gelatin zymography, real-time polymerase chain reaction, and luciferase assays were performed to investigate the effect of the synthetic PPARγ ligand troglitazone on MMP expression. Transcription factor DNA binding was analyzed by electrophoretic mobility shift assay. A Matrigel invasion assay was used to assess the effects of troglitazone on MCF-7 cells. Troglitazone did not affect MCF-7 cell viability. 12- -tetradecanoylphorbol-13-acetate (TPA) induced MMP-9 expression and invasion in MCF-7 cell. However, these effects were decreased by troglitazone. TPA increased nuclear factor κB and activator protein-1 DNA binding, while troglitazone inhibited these effects. The selective PPARγ antagonist GW9662 reversed MMP-9 inhibition by troglitazone in TPA-treated MCF-7 cells. Troglitazone inhibited nuclear factor κB and activator protein-1-mediated MMP-9 expression and invasion of MCF-7 cells through a PPARγ-dependent mechanism.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
https://ejbc.kr/search.php?where=aview&id=10.4048/jbc.2018.21.1.28&code=0096JBC&vmode=FULL
ISSN:1738-6756
2092-9900
DOI:10.4048/jbc.2018.21.1.28